BLPH News and Press, Bellerophon Therapeutics Inc. From 01/18/23

Bellerophon Therapeutics ( NASDAQ: BLPH ) is up 14% in after-hours trading on Thursday after the company completed enrollment in a phase 3 study of INOpulse, a pulsatile nitric oxide delivery system, for fibrotic interstitial lung disease. The 145-patient trial is designed to meas...

WARREN, N.J., Jan. 18, 2023 (GLOBE NEWSWIRE) --  Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced that the last p...

3 Tips for Finding Cheap Penny Stocks Right Now Penny stocks can be a tempting investment opportunity for traders due to their low price point and the potential for large returns. While penny stocks come with a higher level of risk compared to larger, more established stocks, they also of...

Red Hot Penny Stocks Moving Higher After Headlines One of the go-to strategies for finding penny stocks to buy – at least for some traders – is identifying obvious catalysts. One of the most “obvious” typically comes in the form of company news. It takes more dilig...

Bellerophon Therapeutics ( NASDAQ: BLPH ) on Thursday said it had entered into a license agreement for the development and commercialization of its INOpulse nitric oxide delivery system with Baylor BioSciences in China. Shares of the micro-cap clinical-stage biotherapeutics company mo...

WARREN, N.J., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced that it has entered i...

WARREN, N.J., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious diseases, today announced ...

The first patient has been enrolled in a Phase 3 clinical trial, REBUILD, evaluating Bellerophon Therapeutics' (BLPH) INOpulse, a pulsed inhaled nitric oxide therapy, for the potential treatment of fibrotic interstitial lung disease, an umbrella term for a large group of disorders that cause ...

WARREN, N.J., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious diseases, today announced ...

Gainers: DPW Holdings (DPW) +179%.Ideanomics (IDEX) +65%.Fuel Tech (FTEK) +61%.Greenland Technologies (GTEC) +52%.Kaixin Auto (KXIN) +52%.FuelCell Energy (FCEL) +45%.CIIG Merger (CIIC) +37%.Graybug Vision (GRAY) +36%.Beam Global (BEEM) +35%.Marathon Patent (MARA) +33%.Losers: B...